Become a Member
  • Track your favourite stocks
  • Create & monitor portfolios
  • Daily portfolio value
Sign Up
Quickpicks
Add shares to your
quickpicks to
display them here!

Form 38.5(b) - Pfizer Inc

19th Nov 2015 11:48

RNS Number : 3017G
J.P. Morgan Securities LLC
19 November 2015
 

Ap27

 

FORM 38.5(b)

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DEALINGS BY CONNECTED EXEMPT PRINCIPAL TRADERS WITHOUT RECOGNISED INTERMEDIARY STATUS, OR WITH RECOGNISEDINTERMEDIARY STATUS BUT NOT DEALING IN A CLIENT-SERVING CAPACITY

 

 

1. KEY INFORMATION

 

Name of exempt principal trader

J.P. Morgan Securities LLC.

Company dealt in

Pfizer Inc

Class of relevant security to which the dealings being disclosed relate (Note 1)

Common Stock

Date of dealing

18 November 2015

 

2. INTERESTS AND SHORT POSITIONS

 

(a) Interests and short positions (following dealing) in the class of relevant security dealt in (Note 2)

 

Class of relevant security:

Long

Short

Common Stock

Number

(%)

Number

(%)

(1) Relevant securities

5,287,701 0.09

3,761,070 0.06

(2) Derivatives (other than options)

1,239,408 0.02

2,496,887 0.04

(3) Options and agreements to purchase/sell

 5,567,470 0.09

2,404,500 0.04

Total

12,094,579 0.20

8,662,457 0.14

 

 

 

(b) Interests and short positions in relevant securities of the company, other than the class dealt in (Note 2)

 

Class of relevant security:

Long

Short

Number

(%)

Number

(%)

(1) Relevant securities

(2) Derivatives (other than options)

(3) Options and agreements to purchase/sell

Total

 

Ap28

 

 

3. DEALINGS (Note 3)

 

(a) Purchases and sales

 

Purchases/ sales

 

Number of relevant securities

Price per unit (USD)

Purchases

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

Sales

100

3

16,658

9,728

5,000

5,079

4,900

200

400

400

100

9,500

24

2,200

600

8,804

1,600

3,000

1,300

12,272

900

300

1,200

3,200

3,000

200

2,800

100

5,800

 

12,400

200

205

16,658

300

6

200

400

500

900

758

800

400

9,470

33.0350

33.0500

33.0536

33.3000

33.3062

33.3100

33.3122

33.3150

33.3300

33.3350

33.3400

33.3450

33.3500

33.3550

33.3600

33.3621

33.3681

33.3687

33.3700

33.3732

33.3750

33.3775

33.3850

33.3900

33.3950

33.4000

33.4050

33.4100

33.4150

 

33.0366

33.0400

33.0491

33.0536

33.0667

33.0700

33.0800

33.0825

33.0940

33.0967

33.1156

33.1200

33.1325

33.3100

 

(b) Derivatives transactions (other than options transactions)

 

Product name,

e.g. CFD

Nature of transaction

(Note 5)

Number of relevant securities

(Note 6)

Price per unit (USD)

(Note 4)

 

(c) Options transactions in respect of existing relevant securities

 

 

(i) Writing, selling, purchasing or varying

 

Product name,

e.g. call option

Writing, selling, purchasing, varying etc.

Number of securities to which the option relates (Note 7)

Exercise price

Type, e.g. American, European etc.

Expiry date

Option money paid/received per unit (Note 4)

Call Option

Put Option

Purchasing

Purchasing

41,100

50,000

34.00

33.00

American

American

18/12/15

18/12/15

0.70

0.90

 

 

(ii) Exercising

 

Product name,

e.g. call option

Number of securities

Exercise price per unit (Note 4)

Leveraged Accumulator

370

29.1203

+ bought by counterparty at exercise price

 

 

(d) Other dealings (including transactions in respect of new securities) (Note 3)

 

Nature of transaction

(Note 7)

Details

Price per unit

(if applicable) (Note 4)

 

Ap29

 

4. OTHER INFORMATION

 

Agreements, arrangements or understandings relating to options or derivatives

 

Full details of any agreement, arrangement or understanding between the person disclosing and any other person relating to the voting rights of any relevant securitiesunder any option referred to on this form or relating to the voting rights or future acquisitionor disposal of any relevant securities to which any derivative referred to on this form is referenced.If none, this should be stated.

 

 

 

 

 

Is a Supplemental Form 38.5(b) attached? (Note 8)  YES

 

 

Date of disclosure

19 November 2015

Contact name

Tung Le

Telephone number

020 7742 7272

Name of offeree/offeror with which connected

Allergan plc

Nature of connection (Note 9)

Adviser to Allergan plc

 

 

 

SUPPLEMENTAL FORM 38.5(b)

 

 

 

 

IRISH TAKEOVER PANEL

 

DISCLOSURE UNDER RULE 38.5(b) OF THE IRISH TAKEOVER PANEL ACT, 1997, TAKEOVER RULES, 2013

 

DETAILS OF OPEN POSITIONS

 

(This form should be attached to Form 38.5(b)) OPEN POSITIONS (Note 1)

 

Product name,

e.g. call option

Written or purchased

Number of relevant securities to which the option or derivative relates

Exercise price (Note 2)(USD)

Type, e.g. American, European etc.

Expiry date

Call option

 

Purchased

30,000

35.00

American

20/01/17

Call option

Purchased

70,000

37.00

American

20/01/17

Call option

Purchased

363,900

35.00

American

15/01/16

Call option

Purchased

700

38.00

American

15/01/16

Call option

Purchased

1,200,000

34.00

American

20/11/15

Call option

Written

 

2,500

28.00

American

15/01/16

Call option

Written

14,700

30.00

American

15/01/16

Call option

Written

200

37.00

American

15/01/16

Call option

Written

150,000

37.00

American

15/01/16

Call option

Written

50,000

33.00

American

18/12/15

Call option

Written

6,000

34.00

American

18/12/15

Call option

Written

7,600

32.00

American

15/01/16

Call option

Purchased

383,200

34.71

European

21/12/15

Call option

Purchased

383,200

34.71

European

21/12/15

Call option

Purchased

127,794

35.28

European

03/12/15

Call option

Purchased

120,533

35.66

European

12/01/16

Call option

Purchased

48,943

36.47

European

25/01/16

Call option

Written

200,000

33.00

European

16/12/16

Call option

Written

383,200

34.71

European

21/12/15

Put option

Purchased

 

 

30,000

35.00

American

20/01/17

Put option

Purchased

20,000

35.00

American

20/01/17

Put option

Purchased

4,300

30.00

American

15/01/16

Put option

Purchased

2,800

28.00

American

15/01/16

Put option

Purchased

300

32.00

American

15/01/16

Put option

Purchased

150,000

30.00

American

16/09/16

Put option

Purchased

100,000

36.00

American

18/03/16

Put option

Purchased

32,900

32.00

American

15/01/16

Put Option

Purchased

1,000,000

33.50

American

20/11/15

Put option

Written

9,200

33.00

American

19/02/16

Put option

Written

19,100

31.00

American

19/02/16

Put option

Written

5,300

23.00

American

15/01/16

Put option

Written

100,000

30.00

American

15/01/16

Put option

Written

5,600

25.00

American

15/01/16

Put option

Written

250,000

28.00

American

15/01/16

Put Option

Written

500,000

33.00

American

18/03/16

Put Option

Purchased

200,000

33.00

European

16/12/16

Put Option

Written

 

117,900

35.00

American

17/06/16

Put Option

Written

62,400

35.00

American

17/06/16

Put Option

Written

71,300

35.00

American

17/06/16

Put Option

Written

646,800

35.00

American

17/06/16

Put Option

Written

154,500

35.00

American

17/06/16

Put Option

Written

308,100

35.00

American

17/06/16

Put Option

Written

 

139,000

35.00

American

17/06/16

Put Option

Written

 

450,000

35.00

American

15/01/16

Callable Barrier Reverse Convertible Note

Purchased

183,430

32.71

N/A

21/03/17

Callable Barrier Reverse Convertible Note

Purchased

30,572

32.71

N/A

21/03/17

Auto-callable Barrier Reverse Convertible Note

Purchased

45,984

32.62

N/A

17/03/17

Barrier Reverse Convertible Note

Purchased

30,408

34.53

N/A

05/04/16

Equity Linked Note

Purchased

6,740

29.67

N/A

03/02/16

Leveraged Accumulator

Purchased

14,874 +

29.12

N/A

12/09/16

Callable Barrier Reverse Convertible Note

Written

183,430

32.71

N/A

21/03/17

Callable Barrier Reverse Convertible Note

Written

30,572

32.71

N/A

21/03/17

Auto-Callable Barrier Reverse Convertible Note

Written

45,984

32.62

N/A

17/03/17

Barrier Reverse Convertible Note

Written

30,408

34.53

N/A

05/04/16

Equity Linked Note

Written

6,740

29.67

N/A

03/02/16

Leveraged Accumulator

Written

14,874 +

29.12

N/A

12/09/16

Leveraged Accumulator

Written

9,000+

31.70

N/A

04/03/16

Auto-callable Optimization Securities

Written

7,851

27.60

N/A

25/06/20

Equity Linked Note

Written

6,740

29.67

N/A

03/02/16

Callable Barrier Reverse Convertible Note

Written

183,430

32.71

N/A

21/03/17

Callable Barrier Reverse Convertible Note

Written

30,572

32.71

N/A

21/03/17

Auto-Callable Barrier Reverse Convertible Note

Written

45,984

32.62

N/A

17/03/17

Barrier Reverse Convertible Note

Written

30,408

34.53

N/A

05/04/16

Leveraged Accumulator

Written

14,874 +

29.12

N/A

12/09/16

Put Option

Purchased

457,000

27.50

N/A

11/01/16

Callable Barrier Reverse Convertible

Purchased

22,929

32.71

N/A

21/03/17

Auto-Callable Barrier Reverse Convertible Note

Purchased

7,685

32.53

N/A

15/03/17

Auto-Callable Barrier Reverse Convertible Note

Purchased

11,189

32.62

N/A

17/03/17

Barrier Reverse Convertible Note

Purchased

178

2.44

N/A

05/04/16

Equity Link Note

Purchased

31,133

32.12

N/A

15/12/15

Equity Link Note

Written

31,133

32.12

N/A

15/12/15

Equity Link Note

Written

31,133

32.12

N/A

15/12/15

Put Option

Purchased

50,000

33.00

American

18/12/15

+ This instrument is physically settled, and the interest in shares has been calculated as the maximum number of Mylan shares that the counterparty could be obliged to buy at the exercise price

 

Notes

 

1. Where there are open option positions or open derivative positions (except for CFDs), full details should be given.Full details of any existing agreements to purchase or to sell must also be given on this form.

 

2. For all prices and other monetary amounts, the currency must be stated.

 

For full details of disclosure requirements, see Rules 8 and 38.5 of the Rules. If in doubt, consult the Panel.

 

 

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
ISEPKCDQDBDDPDD

Related Shares:

PFZ.L
FTSE 100 Latest
Value8,680.29
Change47.96